172 related articles for article (PubMed ID: 18581275)
1. Expression of homeodomain protein CDX2 in colorectal adenoma and adenocarcinoma.
Bakaris S; Cetinkaya A; Ezberci F; Ekerbicer H
Histol Histopathol; 2008 Sep; 23(9):1043-7. PubMed ID: 18581275
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible factor-1alpha modulates the down-regulation of the homeodomain protein CDX2 in colorectal cancer.
Zheng J; Sun X; Wang W; Lu S
Oncol Rep; 2010 Jul; 24(1):97-104. PubMed ID: 20514449
[TBL] [Abstract][Full Text] [Related]
3. Altered expression of CDX2 in colorectal cancers.
Choi BJ; Kim CJ; Cho YG; Song JH; Kim SY; Nam SW; Lee SH; Yoo NJ; Lee JY; Park WS
APMIS; 2006 Jan; 114(1):50-4. PubMed ID: 16499661
[TBL] [Abstract][Full Text] [Related]
4. CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites.
De Lott LB; Morrison C; Suster S; Cohn DE; Frankel WL
Arch Pathol Lab Med; 2005 Sep; 129(9):1100-5. PubMed ID: 16119980
[TBL] [Abstract][Full Text] [Related]
5. Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.
Winn B; Tavares R; Matoso A; Noble L; Fanion J; Waldman SA; Resnick MB
Hum Pathol; 2010 Jan; 41(1):123-8. PubMed ID: 19800103
[TBL] [Abstract][Full Text] [Related]
6. CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens.
Tanaka S; Saito K; Ito T; Tajima K; Mogi A; Shitara Y; Sano T; Kuwano H
Oncol Rep; 2007 Jul; 18(1):87-92. PubMed ID: 17549351
[TBL] [Abstract][Full Text] [Related]
7. The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas.
Witek ME; Nielsen K; Walters R; Hyslop T; Palazzo J; Schulz S; Waldman SA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8549-56. PubMed ID: 16361536
[TBL] [Abstract][Full Text] [Related]
8. [Expression of Cdx2 protein in colorectal cancer].
Pack JH; Kim TD; Oh HA; Lee EJ; Kim JW; Jang BI; Kim TN; Jung MK; Bae YK
Korean J Gastroenterol; 2005 Sep; 46(3):204-10. PubMed ID: 16179840
[TBL] [Abstract][Full Text] [Related]
9. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas.
Kaimaktchiev V; Terracciano L; Tornillo L; Spichtin H; Stoios D; Bundi M; Korcheva V; Mirlacher M; Loda M; Sauter G; Corless CL
Mod Pathol; 2004 Nov; 17(11):1392-9. PubMed ID: 15205684
[TBL] [Abstract][Full Text] [Related]
10. Loss of MUC2 expression correlates with progression along the adenoma-carcinoma sequence pathway as well as de novo carcinogenesis in the colon.
Mizoshita T; Tsukamoto T; Inada KI; Hirano N; Tajika M; Nakamura T; Ban H; Tatematsu M
Histol Histopathol; 2007 Mar; 22(3):251-60. PubMed ID: 17163399
[TBL] [Abstract][Full Text] [Related]
11. Expression of CDX-2 and Ki-67 in different grades of colorectal adenocarcinomas.
Sen A; Mitra S; Das RN; Dasgupta S; Saha K; Chatterjee U; Mukherjee K; Datta C; Chattopadhyay BK
Indian J Pathol Microbiol; 2015; 58(2):158-62. PubMed ID: 25885126
[TBL] [Abstract][Full Text] [Related]
12. Pituitary adenomas and craniopharyngiomas are CDX2 negative neoplasms.
Schittenhelm J; Psaras T; Meyermann R; Honegger J; Beschorner R
Folia Neuropathol; 2010; 48(2):75-80. PubMed ID: 20602288
[TBL] [Abstract][Full Text] [Related]
13. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors.
Kusaba T; Nakayama T; Yamazumi K; Yakata Y; Yoshizaki A; Nagayasu T; Sekine I
J Clin Pathol; 2005 Aug; 58(8):833-8. PubMed ID: 16049285
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemically detectable Cdx2 is present in intestinal phenotypic elements in early gastric cancers of both differentiated and undifferentiated types, with no correlation to non-neoplastic surrounding mucosa.
Mizoshita T; Tsukamoto T; Inada K; Ogasawara N; Hirata A; Kato S; Joh T; Itoh M; Yamamura Y; Tatematsu M
Pathol Int; 2004 Jun; 54(6):392-400. PubMed ID: 15144397
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of CDX2, β-catenin, and TP53 in inflammatory bowel disease-associated colorectal cancer.
Laurent C; Svrcek M; Flejou JF; Chenard MP; Duclos B; Freund JN; Reimund JM
Inflamm Bowel Dis; 2011 Jan; 17(1):232-40. PubMed ID: 20815042
[TBL] [Abstract][Full Text] [Related]
16. BRAF-mutated microsatellite stable colorectal carcinoma: an aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 immunohistochemical expression.
Landau MS; Kuan SF; Chiosea S; Pai RK
Hum Pathol; 2014 Aug; 45(8):1704-12. PubMed ID: 24908142
[TBL] [Abstract][Full Text] [Related]
17. Expression of mucins, SIMA, villin, and CDX2 in small-intestinal adenocarcinoma.
Zhang MQ; Lin F; Hui P; Chen ZM; Ritter JH; Wang HL
Am J Clin Pathol; 2007 Nov; 128(5):808-16. PubMed ID: 17951204
[TBL] [Abstract][Full Text] [Related]
18. CDX2 downregulation is associated with poor differentiation and MMR deficiency in colon cancer.
Olsen J; Eiholm S; Kirkeby LT; Espersen ML; Jess P; Gögenür I; Olsen J; Troelsen JT
Exp Mol Pathol; 2016 Feb; 100(1):59-66. PubMed ID: 26551082
[TBL] [Abstract][Full Text] [Related]
19. CDX-2 expression is reduced in colorectal carcinomas with solid growth pattern and proximal location, but is largely independent of MSI status.
Okoń K; Zazula M; Rudzki Z; Papla B; Osuch C; Stachura J
Pol J Pathol; 2004; 55(3):9-14. PubMed ID: 15619975
[TBL] [Abstract][Full Text] [Related]
20. Differentiating the undifferentiated: immunohistochemical profile of medullary carcinoma of the colon with an emphasis on intestinal differentiation.
Winn B; Tavares R; Fanion J; Noble L; Gao J; Sabo E; Resnick MB
Hum Pathol; 2009 Mar; 40(3):398-404. PubMed ID: 18992917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
